These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27692643)

  • 1. Elimination of visceral leishmaniasis on the Indian subcontinent.
    Singh OP; Hasker E; Boelaert M; Sundar S
    Lancet Infect Dis; 2016 Dec; 16(12):e304-e309. PubMed ID: 27692643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
    Picado A; Rijal S; Sundar S; Boelaert M
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):839-41. PubMed ID: 23030320
    [No Abstract]   [Full Text] [Related]  

  • 3. Eliminating visceral leishmaniasis in South Asia: the road ahead.
    Rijal S; Sundar S; Mondal D; Das P; Alvar J; Boelaert M
    BMJ; 2019 Jan; 364():k5224. PubMed ID: 30670453
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmission.
    Biswas S; Subramanian A; ELMojtaba IM; Chattopadhyay J; Sarkar RR
    PLoS One; 2017; 12(2):e0172465. PubMed ID: 28222162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.
    Sundar S; Mondal D; Rijal S; Bhattacharya S; Ghalib H; Kroeger A; Boelaert M; Desjeux P; Richter-Airijoki H; Harms G
    Trop Med Int Health; 2008 Jan; 13(1):2-5. PubMed ID: 18290995
    [No Abstract]   [Full Text] [Related]  

  • 6. Can visceral leishmaniasis be eliminated from Asia?
    Joshi A; Narain JP; Prasittisuk C; Bhatia R; Hashim G; Jorge A; Banjara M; Kroeger A
    J Vector Borne Dis; 2008 Jun; 45(2):105-11. PubMed ID: 18592839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the Mathematical Modelling of Visceral Leishmaniasis.
    Rock KS; Quinnell RJ; Medley GF; Courtenay O
    Adv Parasitol; 2016; 94():49-131. PubMed ID: 27756459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U; Joshi R; Agrawal A; Shah V
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK; Dash AP
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis: elimination with existing interventions.
    Matlashewski G; Arana B; Kroeger A; Battacharya S; Sundar S; Das P; Sinha PK; Rijal S; Mondal D; Zilberstein D; Alvar J
    Lancet Infect Dis; 2011 Apr; 11(4):322-5. PubMed ID: 21453873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control.
    Stauch A; Sarkar RR; Picado A; Ostyn B; Sundar S; Rijal S; Boelaert M; Dujardin JC; Duerr HP
    PLoS Negl Trop Dis; 2011 Nov; 5(11):e1405. PubMed ID: 22140589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating drug resistance in visceral leishmaniasis: the challenges.
    Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
    Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.
    Hirve S; Kroeger A; Matlashewski G; Mondal D; Banjara MR; Das P; Be-Nazir A; Arana B; Olliaro P
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005889. PubMed ID: 29023446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral Leishmaniasis-Optimum Treatment Options in Children.
    Sundar S; Agarwal D
    Pediatr Infect Dis J; 2018 May; 37(5):492-494. PubMed ID: 29280784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meeting "Visceral leishmaniasis in Maghreb", 2-4 April 2015 in Tunis. Recommendations].
    Aoun K; Laamrani El Idrissi A; Harrat Z; Marty P
    Bull Soc Pathol Exot; 2015 Aug; 108(3):229-30. PubMed ID: 26002086
    [No Abstract]   [Full Text] [Related]  

  • 16. Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities.
    Joshi AB; Banjara MR; Pokhrel S; Jimba M; Singhasivanon P; Ashford RW
    Kathmandu Univ Med J (KUMJ); 2006; 4(4):488-96. PubMed ID: 18603960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miltefosine for Indian visceral leishmaniasis.
    Roca B
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397
    [No Abstract]   [Full Text] [Related]  

  • 18. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models.
    Le Rutte EA; Chapman LAC; Coffeng LE; Jervis S; Hasker EC; Dwivedi S; Karthick M; Das A; Mahapatra T; Chaudhuri I; Boelaert MC; Medley GF; Srikantiah S; Hollingsworth TD; de Vlas SJ
    Epidemics; 2017 Mar; 18():67-80. PubMed ID: 28279458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.
    Sundar S; Singh OP; Chakravarty J
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):805-812. PubMed ID: 30289007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.